To explore the active components and mechanism of Shenqi Fuzheng Injection for the treatment of non-small cell lung cancer(NSCLC) by network pharmacology and molecular docking technology,and to provide theoretical basis for clinical application.Methods:TCMSP database was used to obtain the active components and targets of Shenqi Fuzheng Injection.The differential genes between NSCLC and normal lung tissue were obtained by NCBI database.And the visual network of common targets was drawed by STRING database and Cytoscape.The DAVID database was used to perform GO analysis and KEGG pathway analysis.The molecular docking technology was carried out by using AutoDock Vina and PyMOL for further verification.Results:A total of 41 active components of Shenqi Fuzheng Injection，2 861 differential genes of NSCLC and 58 common targets were obtained.GO enrichment analysis showed that the biological process mainly involved in the regulation of steroid hormone，oxidative stress response，and multiple chemical and physical responses; KEGG enrichment showed that anti-cancer effect was mainly through TNF pathway，Relaxin pathway，IL-17 pathway，P13K/AKT pathway and Estrogen pathway.The results of molecular docking showed that the main active components had good binding with key targets，and the effectiveness of Shenqi Fuzheng Injection was verified from the molecular level.Conclusion:The therapeutic effect of Shenqi Fuzheng Injection on NSCLC through multi-components，multi-targets and multi-pathways can be proved by network pharmacology and molecular docking，which provides theoretical support for clinical application.